Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition

Oughli, H. A., Gebara, M. A., Ciarleglio, A., Lavretsky, H., Brown, P. J., Flint, A. J., Farber, N. B., Karp, J. F., Mulsant, B. H., Reynolds, C. F., Roose, S. P., Yang, L., Butters, M. A., & Lenze, E. J. (2023). Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Pilot Study of Tolerability, Safety, Clinical Benefits, and Effect on Cognition. The American Journal of Geriatric Psychiatry, 31(3), 210–221. https://doi.org/10.1016/j.jagp.2022.11.013
Authors:
Hanadi Ajam Oughli
Marie Anne Gebara
Adam Ciarleglio
Helen Lavretsky
Patrick J Brown
Alastair J Flint
Nuri B Farber
Jordan F Karp
Benoit H Mulsant
Charles F Reynolds
Steven P Roose
Lei Yang
Meryl A Butters
Eric J Lenze
Affiliated Authors:
Patrick J Brown
Steven P Roose
Subjects:
Ketamine (MeSH)
Author Keywords:
cognition
geriatric
intravenous ketamine
treatment-resistant depression
Publication Type:
Article
Unique ID:
10.1016/j.jagp.2022.11.013
PMID:
Publication Date:
Data Source:
PubMed

Record Created: